China NMPA Inspection - Foshan City, Nanhai District, Lishui Congrong Cosmetics Factory - January 08, 2020

This document, originating from the National Medical Products Administration (NMPA) of China, formally announces an unannounced inspection concerning the Foshan Nanhai District Lishui Congrong Cosmetics Factory. The notification, publicly released on January 8, 2020, serves as an official communication regarding the regulatory oversight of the specified cosmetics manufacturer. Operating under the umbrella of the NMPA, also referred to as the China Drug Administration, the regulatory framework ensures that manufacturers comply with national standards governing the production, quality, and safety of cosmetic products within China. The core purpose of this notification is to make public the initiation or recent completion of a regulatory review at Foshan Nanhai District Lishui Congrong Cosmetics Factory. While the company name is clearly identified, and the type of regulatory action is confirmed as an unannounced inspection, this specific document is limited to being a mere announcement. Consequently, it does not provide explicit details regarding the precise dates when the inspection was conducted. More importantly, it does not enumerate any main violations, non-compliance issues, or deficiencies that may have been identified during the inspection process. Similarly, the notification does not stipulate any required actions, corrective measures, or remedial plans that the Foshan Nanhai District Lishui Congrong Cosmetics Factory must implement to address potential findings. The document's scope is strictly confined to reporting the existence of the unannounced inspection.